Skip to main navigation Skip to search Skip to main content

ORAL UCB0599: A Double-blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Oral UCB0599 In Study Participants With Early Parkinson's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date3/18/22 → 1/29/26

Funding

  • UCB Biopharma SRL (Belgium): $143,043.00